PharmExec Blog

Is Pfizer Ready for Another Acquisition?

After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt.

Read more…

Posted in Deals, Strategy | Tagged , , | Leave a comment

Investment Pros Remain Bullish on Orphans

 An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals.

The group consisting of executives from investment banks, hedge funds, venture capital firms and biopharma companies spoke to the National Organization for Rare Disease (NORD) at its s Rare Diseases and Orphan Products Breakthrough Summit in Alexandria, Virginia on Wednesday last week. Read More »

Posted in Orphan Drugs, pricing | Tagged , , | Leave a comment

Expanded Access: Myths, Truth and Behavior

Not all companies are big, small companies are scared, and myths drive behavior, stated Kay Holcombe, Senior Vice President, Science Policy at Biotechnology Industry Organization (BIO). Read More »

Posted in FDA, Orphan Drugs | Leave a comment

Pharma Feels Impact of US Tax Inversion Legislation

The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation,  says research and consulting firm GlobalData.

Read More »

Posted in Deals, Europe, Global, Strategy | Tagged , , , | Leave a comment
  • Categories

  • Meta